Endoscopic spectral domain optical coherence tomography of murine colonic morphology to determine effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer

Susan LeGendre-McGhee, Photini F S Rice, R. Andrew Wall, Justin Klein, Amber Luttman, Kyle Sprute, Eugene Gerner, Jennifer K Barton

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Optical coherence tomography (OCT) is a minimally-invasive imaging modality capable of tracking the development of individual colonic adenomas. As such, OCT can be used to evaluate the mechanisms and effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer models. The data presented here represent part of a larger study evaluating α-difluoromethylornithine (DFMO) and Sulindac as chemopreventive and chemotherapeutic agents using mice treated with the carcinogen azoxymethane (AOM). 27 A/J mice were included in the chemoprevention study, subdivided into four treatment groups (No Drug, DFMO, Sulindac, DFMO/Sulindac). 30 mm lateral images of each colon at eight different rotations were obtained at five different time points using a 2 mm diameter spectral domain OCT endoscopy system centered at 890 nm with 3.5 μm axial resolution in air and 5 μm lateral resolution. Images were visually analyzed to determine number and size of adenomas. Gross photos of the excised colons and histology provided gold standard confirmation of the final imaging time point. Preliminary results show that 100% of mice in the No Drug group developed adenomas over the course of the chemoprevention study. Incidence was reduced to 71.43% in mice given DFMO, 85.71% for Sulindac and 0% for DFMO/Sulindac. Discrete adenoma size did not vary significantly between experimental groups. Additional experiments are currently under way to verify these results and evaluate DFMO and Sulindac for chemotherapeutic applications.

Original languageEnglish (US)
Title of host publicationProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume8217
DOIs
StatePublished - 2012
EventEndoscopic Microscopy VII - San Francisco, CA, United States
Duration: Jan 22 2012Jan 23 2012

Other

OtherEndoscopic Microscopy VII
CountryUnited States
CitySan Francisco, CA
Period1/22/121/23/12

Fingerprint

Sulindac
Eflornithine
Optical tomography
Optical Coherence Tomography
mice
Colorectal Neoplasms
drugs
tomography
Adenoma
cancer
Chemoprevention
Imaging techniques
Carcinogens
Histology
Endoscopy
carcinogens
Colon
histology
Azoxymethane
incidence

Keywords

  • Chemoprevention
  • Colorectal cancer
  • Optical coherence tomography

ASJC Scopus subject areas

  • Atomic and Molecular Physics, and Optics
  • Electronic, Optical and Magnetic Materials
  • Biomaterials
  • Radiology Nuclear Medicine and imaging

Cite this

LeGendre-McGhee, S., Rice, P. F. S., Wall, R. A., Klein, J., Luttman, A., Sprute, K., ... Barton, J. K. (2012). Endoscopic spectral domain optical coherence tomography of murine colonic morphology to determine effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE (Vol. 8217). [82170E] https://doi.org/10.1117/12.906492

Endoscopic spectral domain optical coherence tomography of murine colonic morphology to determine effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer. / LeGendre-McGhee, Susan; Rice, Photini F S; Wall, R. Andrew; Klein, Justin; Luttman, Amber; Sprute, Kyle; Gerner, Eugene; Barton, Jennifer K.

Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 8217 2012. 82170E.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

LeGendre-McGhee, S, Rice, PFS, Wall, RA, Klein, J, Luttman, A, Sprute, K, Gerner, E & Barton, JK 2012, Endoscopic spectral domain optical coherence tomography of murine colonic morphology to determine effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer. in Progress in Biomedical Optics and Imaging - Proceedings of SPIE. vol. 8217, 82170E, Endoscopic Microscopy VII, San Francisco, CA, United States, 1/22/12. https://doi.org/10.1117/12.906492
LeGendre-McGhee S, Rice PFS, Wall RA, Klein J, Luttman A, Sprute K et al. Endoscopic spectral domain optical coherence tomography of murine colonic morphology to determine effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 8217. 2012. 82170E https://doi.org/10.1117/12.906492
LeGendre-McGhee, Susan ; Rice, Photini F S ; Wall, R. Andrew ; Klein, Justin ; Luttman, Amber ; Sprute, Kyle ; Gerner, Eugene ; Barton, Jennifer K. / Endoscopic spectral domain optical coherence tomography of murine colonic morphology to determine effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 8217 2012.
@inproceedings{e9b79b23d90e4baabd49e7737abe6500,
title = "Endoscopic spectral domain optical coherence tomography of murine colonic morphology to determine effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer",
abstract = "Optical coherence tomography (OCT) is a minimally-invasive imaging modality capable of tracking the development of individual colonic adenomas. As such, OCT can be used to evaluate the mechanisms and effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer models. The data presented here represent part of a larger study evaluating α-difluoromethylornithine (DFMO) and Sulindac as chemopreventive and chemotherapeutic agents using mice treated with the carcinogen azoxymethane (AOM). 27 A/J mice were included in the chemoprevention study, subdivided into four treatment groups (No Drug, DFMO, Sulindac, DFMO/Sulindac). 30 mm lateral images of each colon at eight different rotations were obtained at five different time points using a 2 mm diameter spectral domain OCT endoscopy system centered at 890 nm with 3.5 μm axial resolution in air and 5 μm lateral resolution. Images were visually analyzed to determine number and size of adenomas. Gross photos of the excised colons and histology provided gold standard confirmation of the final imaging time point. Preliminary results show that 100{\%} of mice in the No Drug group developed adenomas over the course of the chemoprevention study. Incidence was reduced to 71.43{\%} in mice given DFMO, 85.71{\%} for Sulindac and 0{\%} for DFMO/Sulindac. Discrete adenoma size did not vary significantly between experimental groups. Additional experiments are currently under way to verify these results and evaluate DFMO and Sulindac for chemotherapeutic applications.",
keywords = "Chemoprevention, Colorectal cancer, Optical coherence tomography",
author = "Susan LeGendre-McGhee and Rice, {Photini F S} and Wall, {R. Andrew} and Justin Klein and Amber Luttman and Kyle Sprute and Eugene Gerner and Barton, {Jennifer K}",
year = "2012",
doi = "10.1117/12.906492",
language = "English (US)",
isbn = "9780819488602",
volume = "8217",
booktitle = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",

}

TY - GEN

T1 - Endoscopic spectral domain optical coherence tomography of murine colonic morphology to determine effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer

AU - LeGendre-McGhee, Susan

AU - Rice, Photini F S

AU - Wall, R. Andrew

AU - Klein, Justin

AU - Luttman, Amber

AU - Sprute, Kyle

AU - Gerner, Eugene

AU - Barton, Jennifer K

PY - 2012

Y1 - 2012

N2 - Optical coherence tomography (OCT) is a minimally-invasive imaging modality capable of tracking the development of individual colonic adenomas. As such, OCT can be used to evaluate the mechanisms and effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer models. The data presented here represent part of a larger study evaluating α-difluoromethylornithine (DFMO) and Sulindac as chemopreventive and chemotherapeutic agents using mice treated with the carcinogen azoxymethane (AOM). 27 A/J mice were included in the chemoprevention study, subdivided into four treatment groups (No Drug, DFMO, Sulindac, DFMO/Sulindac). 30 mm lateral images of each colon at eight different rotations were obtained at five different time points using a 2 mm diameter spectral domain OCT endoscopy system centered at 890 nm with 3.5 μm axial resolution in air and 5 μm lateral resolution. Images were visually analyzed to determine number and size of adenomas. Gross photos of the excised colons and histology provided gold standard confirmation of the final imaging time point. Preliminary results show that 100% of mice in the No Drug group developed adenomas over the course of the chemoprevention study. Incidence was reduced to 71.43% in mice given DFMO, 85.71% for Sulindac and 0% for DFMO/Sulindac. Discrete adenoma size did not vary significantly between experimental groups. Additional experiments are currently under way to verify these results and evaluate DFMO and Sulindac for chemotherapeutic applications.

AB - Optical coherence tomography (OCT) is a minimally-invasive imaging modality capable of tracking the development of individual colonic adenomas. As such, OCT can be used to evaluate the mechanisms and effectiveness of chemopreventive and chemotherapeutic agents in colorectal cancer models. The data presented here represent part of a larger study evaluating α-difluoromethylornithine (DFMO) and Sulindac as chemopreventive and chemotherapeutic agents using mice treated with the carcinogen azoxymethane (AOM). 27 A/J mice were included in the chemoprevention study, subdivided into four treatment groups (No Drug, DFMO, Sulindac, DFMO/Sulindac). 30 mm lateral images of each colon at eight different rotations were obtained at five different time points using a 2 mm diameter spectral domain OCT endoscopy system centered at 890 nm with 3.5 μm axial resolution in air and 5 μm lateral resolution. Images were visually analyzed to determine number and size of adenomas. Gross photos of the excised colons and histology provided gold standard confirmation of the final imaging time point. Preliminary results show that 100% of mice in the No Drug group developed adenomas over the course of the chemoprevention study. Incidence was reduced to 71.43% in mice given DFMO, 85.71% for Sulindac and 0% for DFMO/Sulindac. Discrete adenoma size did not vary significantly between experimental groups. Additional experiments are currently under way to verify these results and evaluate DFMO and Sulindac for chemotherapeutic applications.

KW - Chemoprevention

KW - Colorectal cancer

KW - Optical coherence tomography

UR - http://www.scopus.com/inward/record.url?scp=84858633948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858633948&partnerID=8YFLogxK

U2 - 10.1117/12.906492

DO - 10.1117/12.906492

M3 - Conference contribution

AN - SCOPUS:84858633948

SN - 9780819488602

VL - 8217

BT - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

ER -